February 26, 2025 03:49 PM EST
Pharma

Medicare spend­ing on com­mon di­a­betes drugs sky­rock­et­ed, HHS in­spec­tor gen­er­al finds

Max Bayer

Pharma Reporter

The use of a sub­set of com­mon di­a­betes drugs sky­rock­et­ed in the US Medicare pro­gram over a five-year pe­ri­od end­ing in 2023, ac­cord­ing to a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA meet­ing to pick next win­ter's flu shot is can­celed, in omi­nous sign for US vac­cine pol­i­cy

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

Af­ter re­jec­tion, Re­gen­eron seeks ac­cel­er­at­ed ap­proval of bis­pe­cif­ic for on­ly one of two types of lym­phoma

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Trump blog: NIH nom­i­nee gets Sen­ate date; US agen­cies brace for more job cuts

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times